← All trials
NCT06260163
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2024
- Primary completion
- May 22, 2028
- Completion date
- Aug 14, 2028
- First posted
- Feb 15, 2024
- Last posted
- Oct 24, 2024
- Enrollment
- 120
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.